

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A powder delivery system containing a chamber storing a haemostatic composition comprising dry gelatin powder having a mean particle size in the range of 30-250 μm and hyaluronic acid, ~~said composition having a mean particle size in the range of 30-250 μm~~ ; said chamber having at least one discharge opening sized for distributing said composition.
2. (Original) The delivery system according to claim 1, wherein said discharge opening is sized for distributing said composition to a surface in controlled amounts.
3. (Previously Presented) The delivery system according to claim 1 or 2, further comprising an elongated tip for distributing the composition.
4. (Previously Presented) The delivery system according to claim 1, wherein the delivery system is manually operable.
5. (Original) The delivery system according to claim 4, wherein the delivery system is manually operable by shaking or squeezing the system.
6. (Previously Presented) The delivery system according to claim 1, wherein the delivery system comprises a resilient chamber or bellows.
7. (Previously Presented) The delivery system according to claim 6, wherein the resilient chamber or bellows is adapted to be manually activated to discharge at least part of the composition.

8. (Previously Presented) The delivery system according to claim 1, further comprising a protective structure arranged at the discharge opening.

9. (Original) The delivery system according to claim 8, wherein the protective structure is a skirt portion arranged to extend from the discharge opening.

10-13. (Canceled)

14. (Previously Presented) The delivery system according to claim 1, wherein the powder has a particle size distribution where at least 80% by volume of the particles have a particle size of 30 to 170 μm .

15. (Canceled)

16. (Previously Presented) The delivery system according to claim 1, wherein the moisture content of the powder is at the most 20% (w/w).

17. (Previously Presented) The delivery system according to claim 1, wherein said powder has a poured density in the range of 0.05 to 0.3 g/ml.

18. (Previously Presented) The delivery system according to claim 1, wherein said composition further comprises an agent which improves the adhesive properties of said composition.

19. (Original) The delivery system according to claim 18, wherein said agent is selected from the group consisting of sucrose, glucose, and combinations thereof.

20. (Original) The delivery system according to claim 18 or 19, wherein said agent is admixed with said powder.

21. (Original) The delivery system according to claim 18 or 19, wherein said agent is coated on the surface of said powder.

22. (Previously Presented) The delivery system according to claim 18, wherein said composition comprises 0.1 to 50% (w/w) of said agent, calculated on the total weight of the composition.

23. (Previously Presented) The delivery system according to claim 1, wherein said composition further comprises a coagulation factor.

24. (Previously Presented) The delivery system according to claim 23, wherein said coagulation factor is thrombin.

25. (Previously Presented) The delivery system according to claim 1, wherein said composition does not contain a coagulation factor.

26. (Previously Presented) The delivery system according to claim 1, wherein said delivery system does not contain any propellants.

27-31. (Canceled)

32. (Currently Amended) A method for promoting haemostasis in a patient in need thereof, said method comprising spraying a haemostatic powder composition comprising gelatin having a mean particle size in the range of 30-250 μ m and hyaluronic acid, ~~said composition having a mean particle size in the range of 30-250 μ m~~, wherein said powder is dry, onto at least a portion of an area where bleeding occurs.

33-49. (Canceled)

50. (Previously Presented) The delivery system according to claim 1, wherein the moisture content of the powder is at the most 15% (w/w).

51. (Previously Presented) The delivery system according to claim 18, wherein said agent is selected from the group consisting of chondroitin, chondroitin sulfate, dermatan sulfate and keratan sulfate; aminated dextrans including DEAE-dextran; aminated starch, aminated glycogen, aminated cellulose, aminated pectin, and salts, complexes, and mixtures thereof.

52-59. (Canceled)

60. (Previously Presented) The delivery system according to claim 7, wherein the manual activation occurs by finger pressure.

61. (Canceled)